Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Here’s Why

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped up prior to trading on Tuesday. The stock had previously closed at $9.46, but opened at $9.87. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.47, with a volume of 4,386 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating. According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The stock has a market cap of $16.20 billion, a price-to-earnings ratio of 10.58, a PEG ratio of 3.40 and a beta of 0.10. The stock’s fifty day moving average is $9.26 and its 200-day moving average is $9.66. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings results on Thursday, October 29th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.32% and a net margin of 37.95%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.11 billion. On average, analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.